Ophthotech, Novartis in ex-US pact worth up to $1B-plus, with $200M up front – BioWorld Online

Ophthotech, Novartis in ex-US pact worth up to $1B-plus, with $200M up front
BioWorld Online
Still signing up patients for its phase III trial with Fovista, the antiplatelet-derived growth factor agent that would be used with anti-VEGF therapy in wet age-related macular degeneration (AMD), Ophthotech Corp. pulled down a $200 million upfront ex

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment